# An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

> **NCT03354273** · PHASE3 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 730 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** PET MPI
- **DRUG:** SPECT MPI
- **DRUG:** Pharmacological stress agents

## Key facts

- **NCT ID:** NCT03354273
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-05
- **Primary completion:** 2022-05-05
- **Final completion:** 2022-05-05
- **Target enrollment:** 730 (ACTUAL)
- **Last updated:** 2023-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03354273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03354273, "An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03354273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*